ENDRA Life Sciences (NDRA) Notes Payables (2016 - 2023)

ENDRA Life Sciences has disclosed Notes Payables across 6 years of filings, most recently posting $28484.0 for Q4 2023.

• In Q4 2023, Notes Payables changed 0.0% year-over-year to $28484.0; the TTM figure through Dec 2023 stood at $28484.0 (changed 0.0% YoY), while the FY2023 annual figure was $28484.0, changed 0.0% from the prior year.
• Notes Payables held at $28484.0 in Q4 2023, from $28484.0 in the prior quarter.
• Over the last five years, Notes Payables for NDRA reached as high as $590026.0 in Q3 2019 and fell as low as $28484.0 in Q4 2022.
• The 4-year median for Notes Payables is $28484.0 (2022), against an average of $148633.3.
• The widest YoY moves for Notes Payables: up 0.0% in 2023, down 0.0% in 2023.
• A 4-year view of Notes Payables shows it stood at $298069.0 in 2019, then sank by 87.12% to $38402.0 in 2020, then dropped by 25.83% to $28484.0 in 2022, then changed by 0.0% to $28484.0 in 2023.
• According to Business Quant data, Notes Payables over the past three periods registered $28484.0, $28484.0, and $28484.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.